Sensitivity and specificity of herpes simplex virus-2 serological assays among HIV-infected and uninfected urban Ugandans

Herpes simplex virus type 2 (HSV-2) is a risk factor for HIV-1 infection. We characterized HSV-2 serology assay performance in HIV-positive and HIV-negative Africans. Serostatus for HSV-2 and HIV-1 was determined in 493 serum specimens stored from a community HSV-2 prevalence survey in Kampala, Uganda. HSV-2 serology by Focus HerpeSelect ELISA, Biokit HSV-2 rapid assay and Kalon HSV-2 was compared with HSV-2 Western blot (WB) according to HIV-1 serostatus. Sensitivity/specificity was: 99.5%/70.2% for Focus, 97.0%/86.4% for Biokit and 97.5%/96.2% for Kalon. Focus with Biokit confirmation improved sensitivity/specificity (99.4%/96.8%, respectively). Use of a higher Focus index value cut-off of 2.2 instead of 1.1 increased specificity from 70.2% to 92.4%. Kalon had higher specificity than Focus (P < 0.001). Of commercially available HSV-2 serological assays, Kalon alone, or Focus ELISA followed by Biokit confirmation perform best. Improved HSV-2 assays are needed for HSV-2 and HIV-1 public health activities in Africa.

[1]  J. Lingappa,et al.  Clinical and Therapeutic Issues for Herpes Simplex Virus-2 and HIV Co-Infection , 2012, Drugs.

[2]  J. Baeten,et al.  Daily aciclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial , 2010, The Lancet.

[3]  S. Moses,et al.  Herpes simplex virus type 2 antibody detection performance in Kisumu, Kenya, using the Herpeselect ELISA, Kalon ELISA, Western blot and inhibition testing , 2008, Sexually Transmitted Infections.

[4]  Scott Rose,et al.  Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial , 2008, The Lancet.

[5]  Louise Knight,et al.  Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. , 2008, The New England journal of medicine.

[6]  O. Laeyendecker,et al.  Improved Performance of Enzyme-Linked Immunosorbent Assays and the Effect of Human Immunodeficiency Virus Coinfection on the Serologic Detection of Herpes Simplex Virus Type 2 in Rakai, Uganda , 2008, Clinical and Vaccine Immunology.

[7]  S. Delany-Moretlwe,et al.  Regional Differences in Prevalence of HIV-1 Discordance in Africa and Enrollment of HIV-1 Discordant Couples into an HIV-1 Prevention Trial , 2008, PloS one.

[8]  Connie Celum,et al.  Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. , 2007, The Journal of infectious diseases.

[9]  Vincent Foulongne,et al.  Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. , 2007, The New England journal of medicine.

[10]  A. Meier,et al.  BMC Infectious Diseases BioMed Central Research article Use of "biokit HSV-2 Rapid Assay " to improve the positive predictive value of Focus HerpeSelect HSV-2 ELISA , 2005 .

[11]  A. Wald.  Synergistic interactions between herpes simplex virus type-2 and human immunodeficiency virus epidemics. , 2004, Herpes : the journal of the IHMF.

[12]  R. Hayes,et al.  Performance of Commercially Available Enzyme Immunoassays for Detection of Antibodies against Herpes Simplex Virus Type 2 in African Populations , 2004, Journal of Clinical Microbiology.

[13]  Jennifer S. Smith,et al.  Performance of focus ELISA tests for herpes simplex virus type 1 (HSV-1) and HSV-2 antibodies among women in ten diverse geographical locations. , 2004, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[14]  A. Wald,et al.  Genital herpes and human immunodeficiency virus: double trouble. , 2004, Bulletin of the World Health Organization.

[15]  T. Quinn,et al.  The Effects of Herpes Simplex Virus-2 on HIV-1 Acquisition and Transmission: A Review of Two Overlapping Epidemics , 2004, Journal of acquired immune deficiency syndromes.

[16]  O. Laeyendecker,et al.  Performance of a Commercial, Type-Specific Enzyme-Linked Immunosorbent Assay for Detection of Herpes Simplex Virus Type 2-Specific Antibodies in Ugandans , 2004, Journal of Clinical Microbiology.

[17]  T. Quinn,et al.  Determinants of HIV-1 load in subjects with early and later HIV infections, in a general-population cohort of Rakai, Uganda. , 2004, The Journal of infectious diseases.

[18]  A. Wald,et al.  Time Course of Seroconversion by HerpeSelect ELISA After Acquisition of Genital Herpes Simplex Virus Type 1 (HSV-1) or HSV-2 , 2003, Sexually transmitted diseases.

[19]  Anna Wald,et al.  Serological testing for herpes simplex virus (HSV)-1 and HSV-2 infection. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  R. Ashley.  Performance and use of HSV type-specific serology test kits. , 2002, Herpes : the journal of the IHMF.

[21]  A. Wald,et al.  Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. , 2002, The Journal of infectious diseases.

[22]  R. Brookmeyer,et al.  Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda , 2001, The Lancet.

[23]  J. Zeh,et al.  Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. , 2000, The New England journal of medicine.

[24]  Margaret S. Pepe,et al.  Receiver Operating Characteristic Methodology , 2000 .

[25]  J. Zeh,et al.  Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus-infected men. , 1998, The Journal of infectious diseases.

[26]  Lawrence Corey,et al.  Biological and Virologic Characteristics of Primary HIV Infection , 1998, Annals of Internal Medicine.

[27]  R. Ashley.  Type specific antibodies to HSV-1 and -2 , 1998 .

[28]  E. Abel.  Virologic characteristics of subclinical and symptomatic genital herpes infections , 1996 .

[29]  J. Feldman,et al.  Increased Genital Shedding of Herpes Simplex Virus Type 2 in HIV-Seropositive Women , 1995, Annals of Internal Medicine.

[30]  R L Ashley,et al.  Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera , 1988, Journal of clinical microbiology.